Characteristics of 14 patients with CML before SCT
. | Disease stage at analysis . | BCR-ABL translocation . | Time from diagnosis to analysis, mo . | . | T-cell response . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|
| UPN . | . | . | . | Treatment . | PR1 . | WT1 . | BCR-ABL . | ||
| 16 | CML-CP | b3a2 | 2 | HU | N | N | N | ||
| 17 | CML-CP | NA | 4 | BU, HU | Y | Y | ND | ||
| 25 | CML-CP | NA | 15 | BU | N | Y | ND | ||
| 38 | CML-CP | NA | 3 | HU | Y | Y | ND | ||
| 41 | CML-CP | b3a2 | 24 | HU | Y | Y | N | ||
| 181 | CML-CP | b3a2 | 2 | HU, IFN-α | Y | N | N | ||
| 199 | CML-CP | b2a2 | 15 | HU | Y | Y | ND | ||
| 210 | CML-LBC, 2nd CP | b2a2 | 4 | HU, IFN-α, hyper CVAD-3 cycles | Y | Y | Y | ||
| 241 | CML-CP | b3a2 | 3 | HU | N | N | N | ||
| 254 | CML-CP | NA | 8 | HU | Y | Y | Y | ||
| 262 | CML-CP | b3a2/b2a2 | 5 | HU | N | N | N | ||
| 283 | CML-MBC, 2nd CP | b3a2/b2a2 | 84 | HU, imatinib mesylate | Y | N | Y | ||
| 319 | CML-CP | b3a2 | 4 | HU, anagrelide | N | N | N | ||
| 327 | CML-CP | b3a2 | 9 | HU, Ara-C | N | N | ND | ||
. | Disease stage at analysis . | BCR-ABL translocation . | Time from diagnosis to analysis, mo . | . | T-cell response . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|
| UPN . | . | . | . | Treatment . | PR1 . | WT1 . | BCR-ABL . | ||
| 16 | CML-CP | b3a2 | 2 | HU | N | N | N | ||
| 17 | CML-CP | NA | 4 | BU, HU | Y | Y | ND | ||
| 25 | CML-CP | NA | 15 | BU | N | Y | ND | ||
| 38 | CML-CP | NA | 3 | HU | Y | Y | ND | ||
| 41 | CML-CP | b3a2 | 24 | HU | Y | Y | N | ||
| 181 | CML-CP | b3a2 | 2 | HU, IFN-α | Y | N | N | ||
| 199 | CML-CP | b2a2 | 15 | HU | Y | Y | ND | ||
| 210 | CML-LBC, 2nd CP | b2a2 | 4 | HU, IFN-α, hyper CVAD-3 cycles | Y | Y | Y | ||
| 241 | CML-CP | b3a2 | 3 | HU | N | N | N | ||
| 254 | CML-CP | NA | 8 | HU | Y | Y | Y | ||
| 262 | CML-CP | b3a2/b2a2 | 5 | HU | N | N | N | ||
| 283 | CML-MBC, 2nd CP | b3a2/b2a2 | 84 | HU, imatinib mesylate | Y | N | Y | ||
| 319 | CML-CP | b3a2 | 4 | HU, anagrelide | N | N | N | ||
| 327 | CML-CP | b3a2 | 9 | HU, Ara-C | N | N | ND | ||
UPN indicates unique patient number; CML-CP, CML chronic phase; HU, hydroxyurea; NA, not available; BU, busulphan; IFN-α, interferon-α; CML-LBC, CML lymphoid blast crisis; hyper CVAD, cyclophosphamide, doxorubicin, vincristine, and dexamethasone; CML-MBC, CML myeloid blast crisis; Ara-C, cytosine-arabinoside; and ND, not done.